KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.98

Vortioxetine versus SSRI/SNRI with Pregabalin Augmentation in Treatment-Resistant Burning Mouth Syndrome: A Prospective Clinical Trial.

Daniela Adamo, Federica Canfora, Giuseppe Pecoraro, Stefania Leuci, Noemi Coppola, Gaetano Marenzi, Giulia Ottaviani, Katia Rupel, Luca Pellegrini, Massimo Aria, Luca D'Aniello, Michele Davide Mignogna, Umberto Albert

Curr Neuropharmacol 23(7) 800-819

PMID40016875
PMCIDPMC12163466
DOI10.2174/1570159X22999240729103717
发表日期2025-02-28
入排依据:未发现恶性肿瘤人群证据。
摘要

摘要

OBJECTIVES: The treatment of Burning Mouth Syndrome (BMS) represents a challenge in tailoring appropriate medication for individual patients. The augmentation of pregabalin to conventional treatment has shown promising outcomes in relieving pain and improving the quality of life in chronic pain conditions. This study aimed to compare the efficacy of vortioxetine with other antidepressants (SSRIs/SNRIs) in combination with pregabalin in a cohort of unresponsive BMS patients and to predict treatment response by using clinical data. METHODS: A 52-week randomized, open-label, comparative clinical study was conducted, enrolling 203 BMS patients previously treated with one antidepressant for 12 weeks and non-responders to the treatment (clinical trial registration: NCT06025474). The study sample included two groups: Group A (136) received vortioxetine, while Group B (67) received SSRIs/SNRIs. Pregabalin (75 mg/day) was added to both groups, with a potential dosage increase to 150 mg/day for inadequate responders after 12 weeks. Treatment response was assessed with VAS and SF-MPQ, HAM-A, and HAM-D scores at 12, 24, 36, and 52 weeks. Stepwise logistic regression analysis was used to predict treatment response. RESULTS: A total of 84 (61.8%) BMS patients in Group A and 39 (58.2%) in Group B showed treatment response. Group A reported a faster onset of action compared to Group B (44.8% versus 22.4% at time 1; p:0.002**) and lower adverse event rates (8.8% versus 20.8%; p:0.001). CONCLUSION: The addition of pregabalin to vortioxetine may be considered a potential treatment option for BMS. Further research is required to corroborate these findings and optimize personalized treatment approaches for BMS patients. CLINICAL TRIAL REGISTRATION NUMBER: ClinicalTrials.gov (NCT06025474).

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。